Drug Profile
Research programme: vascular endothelial growth factor inhibitors - Encysive
Alternative Names: Angiogenesis inhibitors research programme - Encysive; TBC 2576; Vascular endothelial growth factor inhibitors research programme - EncysiveLatest Information Update: 24 Aug 2006
Price :
$50
*
At a glance
- Originator Encysive Pharmaceuticals
- Class
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 24 Aug 2006 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 21 Jan 2002 Preclinical development for Solid tumours in USA (Unknown route)